GC方案作为诱导方案治疗老年局部晚期非小细胞肺癌的临床观察  

Clinical observation of GC used as induction regimen for elderly patients with locally advanced non-small cell lung cancer

作　　者：孙志华[1] 郑红敏[1] 张凌云[1] 

机构地区：[1]襄樊市中心医院肿瘤科,湖北襄樊441021

出　　处：《现代肿瘤医学》2011年第7期1358-1360,共3页Journal of Modern Oncology

摘　　要：目的:评价吉西他滨联合卡铂在老年不可手术的局部晚期非小细胞肺癌(non-small cell lung canc-er,NSCLC)作为诱导方案的疗效和安全性。方法:对于有明确的病理或细胞学诊断,年龄在65-75岁的晚期不可手术的NSCLC患者78例,应用GEM联合CBP化疗,GEM1000mg/m2静脉滴入第1、8天,CBP AUC为4,在第1天给药。21d为1个周期,共2个周期。并按RECIST标准评价疗效和WHO不良反应分级标准记录不良反应。结果:可评价的78例患者,共完成156个周期化疗,CR 0例,PR 32例,NC 37例,PD 9例,总有效率为41.0%。主要不良反应为骨髓抑制和消化道反应。结论:GEM联合CBP作为老年不可手术的晚期NSCLC诱导治疗是安全有效的,不良反应可以接受。Objective：To evaluate the efficacy and safety of gemcitabine（GEM） and carboplatin（CBP） used as induction regimen in the treatment of elderly patients with locally advanced unresectable NSCLC.Methods： All 78 cases of elderly patients have been cytologically and pathologically confirmed with locally advanced unresectable NSCLC,the age of the patients ranged from 65 to 75.Patients were treated with the combined regimen of gemcitabine and cisplatin.GEM 1 000mg/m2 intravenously injected by drip on the 1 st,8 th day and the dosage of CBP was AUC 4 that was used on the 1 st day,21 days apart to each cycle,most patients received 2 cycles.Treatment response was evaluated according to the criteria of RECIST（Response Evaluation Criteria in Solid Tumor）,side effect of the regimen was judged based on WHO criteria.Results： All 78 patients were evaluable and received a total of 156 cycles chemotherapy.There were no complete regression but 32 cases had partial regression（PR）,37 cases with no change（NC） and 9 cases with progression disease（PD）.The overall response rate was 41.0%.The main side effects were hematological toxicity.Conclusion： GC regimen could be used as induction treatment for elderly patients with locally advanced unresectable NSCLC,and the regimen is well tolerated and safe.

关 键 词：老年患者 非小细胞肺癌 吉西他滨 卡铂 诱导化疗 

分 类 号：R734.2[医药卫生—肿瘤]